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Chapter 1. Introduction 
 
1.1. Obesity and its risk 
The presence of obesity and diabetes in the modern world are devastating. More than 1 billion 
adults are either overweight (Body mass index (BMI) >25) or obese (BMI>30), and more than 150 
million adults have diabetes, most of which is type 2 diabetes (T2D). Also, about 25% of children 
in the USA alone are overweight or obese which puts them into the risk of developing T2D. 
Worrisome is that these numbers are expected to double by the year 2025 worldwide, with 
particularly drastic impact in developing countries [1]. Obesity develops when energy intake 
exceeds energy expenditure, resulting in the accumulation of white adipose tissue (WAT) in the 
body (Figure 1). Most commonly it is usually the result of an imbalance between the calorie dense 
food intakes, reduced physical activity (lifestyle), and sometimes inability of the brain central 
nervous system (CNS) to suppress the appetite [2].                
Obesity possesses a strong risk factor for several metabolic diseases; such as T2D, 
hyperlipidaemia, atherosclerosis and non-alcoholic fatty liver disease (NALFD). Several current 
anti-obesity drugs that aim to reduce food intake cause severe psychiatric or cardiovascular side 
effects [3,4]. Therefore, alternative safety therapeutic strategies are urgently needed to combat 
obesity. 
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1.2. Brown adipose tissue (BAT): A novel target to combat obesity 
Based on the function, cell structure, location and colour, adipose tissue are divided into two 
major types: White adipose tissue (WAT) and BAT. WAT is the primary site of fat (energy) 
storage in the form of triglycerides (TGs), whereas BAT contains multiocular lipid droplets and 
has higher mitochondrial content, which gives it the colour brown. BAT is capable of burning fat 
and is specialised in heat production and therefore energy expenditure [5]. BAT is necessary for 
thermogenesis and energy balance in small mammals, and BAT induction in mice promotes 
energy expenditure, which leads to reduced adiposity and also protects mice from diet-induced 
obesity [6,7].  Also, the ablation of BAT activity results in reduced energy expenditure and 
increased weight gain in response to high-fat diet [8]. Mitochondria in the brown adipocytes 
express uncoupling protein-1 (UCP-1), which uses lipids and carbohydrates to generate heat by 
uncoupling electron transport from oxidative phosphorylation [9] (Figure 2). Activation of brown 
adipocytes results in fatty acid (FAs) oxidation for which lipids (fats) and carbohydrates are 
utilized from outside the cell [10].         
Recent studies have revealed the ability of certain WAT depots to activate thermogenesis upon 
exposure to cold and hormonal stimuli [11,12]. A subpopulation of cells in inguinal WAT (iWAT), 
known as “beige” cells, expresses UCP-1 and carries out thermogenesis. Thus, promoting the 
development and function of brown and beige fat appears as an attractive treatment for obesity and 
obesity-related metabolic diseases [13]. 
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1.3. Pharmacological approach towards obesity 
Until now the therapeutic strategies intended towards reducing the hunger or increasing the satiety 
have not been successful. Calorie restriction in combination with exercise is effective in short-
term, but long-term weight maintenance is difficult and weight regains, sometimes rising above 
previous weight is common [14-16].  
Appetite suppressant drugs such as sibutramine and rimonabant have both been withdrawn from 
the market due to their severe short and long-term side effects like cardiovascular disorders, 
stroke, and psychiatric disorders. A gastrointestinal lipase inhibitor, orlistat, which increases 
satiety, is available. However, this drug has limited efficacy and causes serious side effects. Hence, 
an alternative strategy is to increase energy expenditure, via BAT activation, as a means to prevent 
weight gain and to induce weight loss. 
 
1.4. Drugs activating BAT: enhancing thermogenesis 
Norepinephrine contained in sympathetic neuronal fibres in BAT interacts with β3 adrenergic 
receptors (β3 AR) present in the adipocyte cell surface [17]. Activation of β3AR increases the 
cyclic adenosine monophosphate (cAMP), which subsequently results in overexpression of UCP-1 
resulting in the increased glycolysis [18]. Thus, one approach is the agonist-mediated activation of 
β3AR on brown adipocyte as a strategy for studying BAT biology, and as a potential therapeutic 
approach for diabetes and obesity. Apart from this elevating norepinephrine levels, adenylyl 
cyclase and peroxisome proliferator-activated receptor γ (PPARγ) are other possible strategies to 
combat obesity and related disorders [19]. Based on this, the drugs used for BAT activation can be 
classified broadly into four categories (Figure 3). 
Category 1: β3 AR agonist, category 2: Norepinephrine altering drugs, category 3: PPARγ 
activators, and category 4: Other drugs/ natural products. 
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1.4.1 Category 1 drug: β3 adrenergic receptor agonists 
Currently, a β3AR agonist is approved only for the treatment of overactive bladder (OAB) [20]. 
The β3AR are G-protein coupled receptors (GPCR) and are found abundantly on brown 
adipocytes [21-24].  
BAT is innervated by sympathetic nerves containing catecholamine norepinephrine, which activate 
β3AR. A significant attempt has been made to assess β3AR selective agonists as potential 
therapeutic agents for the treatment of obesity [25].  
Table 1 shows the list of some selective β3AR agonists. BRL37344 a selective β3AR agonist is 
known to be selective for adipocyte lipolytic response [26]. Also, prolonged treatment with 
BRL37344 causes a 34-fold increase in basal glucose utilisation index (GUI) of BAT specifically 
[27]. CL316,243 is another highly selective β3AR agonist [28]. In previous studies, CL316,243 
activated BAT  [29] and promoted BAT mitochondrial proliferation and energy expenditure [30]. 
In initial human studies with CL316,243 energy expenditure after eight weeks in lean young males 
did not differ from baseline [31] and because of its poor bioavailability in humans, CL 316,24 
trials were discontinued in humans. 
Apart from CL316,243, there are three closely related derivatives, rafabegron, mirabegron and 
solabegron which are being pursued clinically for use in OAB and irritable bowel syndrome (IBS) 
[20]. Rafabegron exhibited some increase in energy expenditure at the highest dose in obese men 
and women [32].  Solabegron which is studied for its effect in IBS has not been studied for effects 
on energy expenditure. However, mirabegron a β3AR selective agonist [33] is approved for use in 
OAB only [34]. Mirabegron was shown to activate rat [35] BAT and human [36] BAT  activity. 
Talibegron and ZD7114 are selective β3AR drugs which increase energy expenditure via non-
shivering thermogenesis  [37]. In contrast, ZD7114  has been reported to have antagonist 
properties towards β3AR in isolated rat ileum [38]. Also, ZD7114 did not affect 24-hour energy 
expenditure in obese women and men, while talibegron had a very minimal stimulatory effect on 
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energy expenditure [39]. Their role in weight loss or diabetes is therefore not satisfactory. 
ICID7114 has been reported to stimulate BAT activity and oxygen consumption in canine studies 
[40,41]. However, no further studies on its effect on weight loss or diabetes have been published. 
Also, another selective β3AR drug L-796568 did not show any significant effect in lipolysis or 
thermogenic activity in nondiabetic men [42]. Other clinically used β3AR agonists, amibegron 
[43,44] have also been discontinued.  
 
1.4.2 Category 2 drugs: Norepinephrine altering drugs 
Norepinephrine stimulates β3AR and cold temperatures may increase metabolism indirectly by 
raising norepinephrine levels [45,46]. The BAT capacity of thermogenesis is enhanced with raise 
in norepinephrine level [47]. List of drugs, which elevate norepinephrine levels, is listed in table 2. 
 
1.4.3 Category 3 drugs: PPARγ activators (glitazones) 
Activation of PPARγ by the glitazones class of drugs affects carbohydrate and lipid metabolism by 
several mechanisms and have been studied for its effect in the treatment of T2D [48].  Knowing 
the significant role of brown adipocytes in the increase of energy expenditure, an increase of 
brown fat adipogenesis by glitazones could add to the advantageous effects of these drugs on 
insulin sensitivity in humans. Table 3 shows the different types of glitazones and their status. 
Rosiglitazone promotes brown pre-adipocyte cell differentiation and increases rat BAT mass. Also, 
treatment of human pre-adipocytes with rosiglitazone caused an increase in levels of UCP-1 
mRNA [49].  Previous studies have shown increased BAT activity in rodents treated with 
troglitazone [50]. On the other hand, ciglitazone reduced blood glucose, triglycerides, and food 
consumption without affecting body weight in obese hyperglycemic mice. However, it did show a 
reduction in human blood sugar but is currently not used in any medication form [51]. 
Troglitazone increases glucose transporter type 4 (GLUT4) expression in obese T2D rat models 
	 6	
and increases insulin sensitivity in non-insulin-dependent diabetes mellitus, but this drug comes 
with grave liver-damaging side effects [52]. It was used as an anti-diabetic but has now been 
discontinued due to its severe side effects. Pioglitazone is used for the treatment of diabetes 
mellitus, but it causes severe urinary bladder side effects in some cases [53,54]. Balaglitazone 
reduced blood glucose levels in obese rats [53,54].  
Rivaglitazone also reduces blood glucose levels by increasing insulin sensitivity in diabetic animal 
models. The drug also improves glycemic control in T2D patients. The drug is under trial for the 
treatment of T2D [55,56]. Darglitazone showed an increase in BAT activity [57], but, clinical 
development of darglitazone has been discontinued. 
 
1.4.4 Category 4 drugs: Other products/Natural products 
Nicotine causes the release of catecholamine, including norepinephrine, which initiates 
thermogenesis in BAT for energy expenditure [58].  Nicotine also promotes the resting metabolic 
rate, all of which contribute to the reduction of obesity [59].  
Forskolin is another BAT activator known for inducing thermogenesis [60]. It stimulates the 
adenylyl cyclase enzyme directly and enhances the intracellular levels of cAMP [61]. Caffeine 
raises BAT temperature with limited impact on core temperature and oxygen consumption in BAT 
mitochondria suggesting caffeine activates BAT thermogenesis [62]. Adenosine receptors, A2A 
have also been suggested to play a role in BAT activation [63]. Previous studies have shown a 
significant decrease in adiposity after continued ingestion of capsinoids (capsaicin) in humans. 
BAT is connected in the capsinoid-induced boost in energy expenditure. Raised UCP1 expression 
was also noted in rats administered with capsinoids for two weeks [64]. Capsinoid ingestion 
enhances energy expenditure through the activation of brown adipose tissue in humans [65].  
Curcumin is a yellow pigment found in turmeric and has been studied as a treatment for obesity-
related conditions. It interacts directly with adipocytes, pancreatic cells, macrophages, and muscle 
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cells. Curcumin has been used to reverse insulin sensitivity, hyperglycaemia, hyperlipidaemia, and 
other symptoms linked to obesity. It also has the capability of binding to PPARγ in order to 
stimulate differentiation of human adipocytes [66]. It has been further demonstrated to increase 
cold tolerance in mice and to promote β3AR gene expression in inguinal WAT. Elevation of 
plasma norepinephrine levels was enhanced with curcumin treatment [67]. A list of natural 
products, which have the potential to activate BAT and energy expenditure, is provided in table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 8	
1.5 Octacosanol: A long chain fatty alcohol 
Over the past 10 years, nutritional supplements, or nutraceuticals, have become increasingly 
popular among the general public. One such supplement, policosanol, has been the subject of 
numerous studies. 
Policosanol is a mixture of very-long-chain saturated fatty alcohols purified from natural sources 
such as rice bran, wheat, sugarcane and beeswax, whose main component is octacosanol 
(CH3(CH2)26CH2O14), a high molecular weight primary aliphatic alcohol [68,69].  
Octacosanol has a number of indications for its use, many of which are currently being researched. 
Previous studies have demonstrated that octacosanol lowers blood cholesterol [70-74], suppresses 
platelet aggregation [75,76], reduces inflammation [77-79], increases athletic performance [80-
83], protects cells [84], alleviates stress and restores stress-affected sleep [85]. Thus, octacosanol 
(policosanol) could be used as a drug or food supplement without any side effects. 
 
1.5.1 Lipid lowering effect of octacosanol  
A lot of research investigating the potential of policosanol in lowering blood cholesterol had been 
published in the recent years. Effect of policosanol and octacosanol has been studied in a wide 
range of subjects including experimental animals, healthy volunteers, and elderly patients with 
hypercholesterolemia. 
Cholesterol is an essential component in the body as it is a vital component of cell membranes, but 
high cholesterol levels can cause hypercholesterolemia and eventually atherosclerosis leading to 
coronary heart disease (CHD). There are six important lipoprotein transporters involved in the 
transportation of cholesterol in the body high-density lipoproteins (HDLs), low-density 
lipoproteins (LDLs), intermediate-density lipoproteins, very low-density lipoproteins, 
chylomicron remnants, and chylomicrons. High levels of HDL are desirable as it plays a major 
role in maintaining cholesterol homeostasis in the body by transporting cholesterol from the 
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peripheral tissues to the liver [86]. Transportation of cholesterol in the blood plasma is performed 
by LDL, which helps incorporate cholesterol into cell membranes. LDL also acts as an essential 
precursor during biosynthesis of steroids. 
LDL receptors on cells take up the LDL via a mechanism known as endocytosis. Also, there are 
cells on the hepatocytes that bind to the LDL and remove LDL from the blood. More the number 
of LDL receptors, more LDL will be removed, which is desirable. Increase in LDL can cause 
deficiency in the binding mechanisms, known as type II hypercholesterolemia. That is why 
treatment for hypercholesterolemia targets towards increasing HDL and decreasing total and LDL 
cholesterol [87,88].  
During a motor endurance experiment researchers observed altered hepatic and serum lipid 
concentration in mice receiving octacosanol [89] and began to investigate the role of octacosanol 
as a cholesterol-lowering agent. 
Being a natural compound, policosanol has shown to be a very safe agent in rodents and monkeys, 
without any major side effects [90]. 
A study was published in 1995, highlighting the beneficial effects of octacosanol supplementation 
in rats fed a high fat [71]. In the experiment, rats were fed a high-fat or normal fat diet for 4 
weeks; one group on each diet was also given octacosanol. The results showed that 
supplementation of the high fat diet with octacosanol causes a significant decrease in the weight of 
perirenal adipose tissue. In further experiments, effect of octacosanol on the enzymes involved in 
lipid metabolism was investigated and it was found that the rate-limiting step in the esterification 
of fatty acid into triacylglycerol was decreased by octacosanol in rats fed a high-fat diet. This 
indicated that a step in the cholesterol biosynthetic pathway was inhibited by octacosanol, which 
was dependent on dietary fat content.  
In order to check the tolerability of policosanol, a study was conducted in which healthy 
volunteers were given policosanol (10 or 20 mg) or placebo in two divided doses for 20 days. 
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Researchers observed that the subjects taking policosanol had a significant decrease in their serum 
cholesterol levels. Similarly, subjects receiving higher dose of policosanol (20mg) also had 
significant decrease in their LDL levels and increase in HDL levels. Surprisingly, subjects 
receiving placebo showed an increase in serum cholesterol and LDL levels. Also, there was good 
tolerance in all subjects taking the policosanol [91].  
Ideally, high cholesterol should be managed with a low-fat diet; if there is little improvement, a 
statin is often added. Normal levels are those less than 6.5 mM although other risk factors such as 
family history, obesity, diabetes and smoking must be taken into account when determining the 
risk of developing atherosclerosis. 
A variety of statins are available such as atorvastatin, fluvastatin, pravastatin, and simvastatin. All 
of these work by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase in 
the process of cholesterol synthesis [92]. 
Statins have many side effects such as myositis and other muscle effects, headache, 
gastrointestinal effects, rash, angioedema, altered liver function, and hepatitis. These drugs 
therefore should not be used in patients with renal failure or in people with a high alcohol intake 
whose liver function may be compromised.  
Recently, one of the most popularly prescribed statins, cerivastatin, was withdrawn from the 
market after 31 deaths occurred due to rhabdomyolysis, a severe form of myositis, causing 
myoglobinuria and acute renal failure [93]. Policosanol therefore could be a useful alternative to 
this group of drugs because it inhibits the earlier steps of cholesterol biosynthesis.  
In a double blind randomized study [94], effect of policosanol and pravastatin on lipid profile of 
older hypercholesterolemic patients of both sexes was investigated. Patients started a 6-week 
cholesterol lowering diet and lipid-lowering medication was stopped at the recruitment stage. 
Patients received 10 mg of policosanol and pravastatin for 8 weeks. It was found that the 
policosanol was more effective in lowering LDL ratio and the ratios of LDL to HDL and total 
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cholesterol to HDL compared to pravastatin. Moreover, patients receiving pravastatin had 
significantly higher serum transaminase and serum creatine phosphokinase levels, suggesting risk 
of hepatotoxicity and myositis. In another study, effect of policosanol with those of fluvastatin was 
compared [95]. Seventy elderly women received 20mg/day fluvastatin and 10mg/day policosanol. 
This study also identified increased transaminase, suggesting muscle deterioration and safety 
issues with the use of statins. 
Another comparative study between policosanol and lovastatin found similar results [96]. Many 
placebo studies have investigated the effects of policosanol on hypercholesterolemia [97-102] and 
in all cases the effects seen from policosanol were similar: LDL cholesterol decreased and HDL 
cholesterol increased slightly. 
From these studies octacosanol appear to be a good lipid-lowering agent without any serious side 
effects. Combination of octacosanol with lower doses of statins could be a possibility in patients 
with high cholesterol levels. Also, octacosanol may be used as a prophylactic treatment as one 
study observed lowered cholesterol levels in young healthy volunteers supplemented with 
octacosanol [103]. Hence, octacosanol may also be useful in healthy people. 
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1.5.2 Does octacosanol possess anti obesity property? Hypothesis and aim  
A study investigating the biodistribution and metabolism of radiolabeled octacosanol in rats after 
oral administration has demonstrated higher octacosanol radioactivity in the liver, muscle and 
adipose tissue, especially BAT [104]. Moreover, previous studies have demonstrated that 
shortened saturated fatty acids (FAs; myristic, palmitic and stearic) and unsaturated FAs (oleic, 
palmitoleic) are formed after oral administration of policosanol to monkeys [105]. These FAs 
might be utilized for energy expenditure via β-oxidation [106]. Policosanol, a long chain fatty 
alcohol is converted into fatty acid and the reaction is catalysed by fatty alcohol: NAD 
oxidoreductase (FAO) [107]. FAO is a membrane-bound multi-component enzyme complex that 
consists of fatty alcohol dehydrogenase (FADH) and fatty aldehyde dehydrogenase (FALDH), 
which acts sequentially to convert fatty alcohol to aldehyde and fatty acids [108,109] (Figure 4).  
The β-oxidation of FAs is critical for the function of BAT and beige fat and hence thermogenesis 
[110,111]. Recent studies using experimental models and humans suggest that the long chain 
saturated FAs, mainly stearic acid (C18:0), regulate mitochondrial function [112,113]. Moreover, 
the ELOVL family member 6 (Elovl6), a microsomal enzyme responsible for converting C16 FAs 
into C18 species, has been suggested to regulate BAT thermogenic capacity [114]. 
Considering that the longer fatty acids could be preferred substrates for thermogenesis and the 
abovementioned effects of octacosanol or policosanol on lipid metabolism, their role in the 
prevention or treatment of obesity and in the thermogenic function of brown and beige adipocytes 
has not yet been established. In the present study, we investigated anti-obesity and thermogenic 
function of octacosanol and policosanol in mice.  
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Chapter 2. Materials and methods 
2.1 Animals and growth conditions 
All animal husbandry and animal experiments complied with regulations of the University of 
Tsukuba for animal experiments and were approved by the Animal Experiment Committee of the 
University of Tsukuba. Seven-week-old C57BL/6 mice were obtained from CLEA Japan (Tokyo, 
Japan). Mice were housed in colony cages under a 12 h light/12 h dark cycle, with unlimited 
access to food and water. At 10 weeks of age, mice were randomly divided into the following four 
groups: chow group (fed on standard chow with vehicle (10 mg/ml Acacia-gum water), HFD 
group (fed with vehicle treatment), the HFD + octacosanol group (60 mg/kg/day; Sigma-Aldrich, 
Tokyo, Japan), and HFD + policosanol group (60 mg/kg/day). Octacosanol, policosanol, or the 
same volume of vehicle was administered via oral gavage once every four weeks. At the end of 
four weeks, all mice were sacrificed in the early light phase in a non-fasting state. 
 
2.2 Dual-energy x-ray absorptiometry (DEXA) analysis 
PIXImus2 DEXA (GE Medical Systems Lunar) was used to measure weight and percent of lean 
body tissue and fat mass. 
 
2.3 Metabolic measurements 
Glucose, insulin, TG, TC and FFA levels in plasma and TG and TC levels in the liver were 
determined, as described previously [115]. Bloos samples were taken during the light phase after 
food deprivation for four hours. 
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2.4 Body temperature measurement 
Core body temperature was measured between 5:00 PM and 6:00 P.M. using a rectal probe 
attached to a digital thermometer (RET-3 rectal probe, BRC BDT-100 thermometer; Physitemp, 
Clifton, NJ).) 
 
2.5 Histological analysis 
Interscapular BAT (iBAT), iWAT, and eWAT were removed, fixed in 10% buffered formalin, 
embedded in paraffin, cut into 4 µm thick sections and used for hematoxylin and eosin (H&E) 
staining and immunohistochemistry as described previously [116]. Immunohistochemical staining 
for UCP-1 (1:400, ab10983; Abcam, Cambridge, UK) and CD68 (1:400, MCA1957GA; Bio-Rad, 
Hercules, USA) primary antibodies and detection with secondary antibodies (anti-rabbit IgG, 
Alexa Fluor 555 conjugate, 1:500, #4413; Cell Signalling Technology Japan, Tokyo, Japan or goat 
abti-rat IgG, Alexafluor 488 conjugate, 1:500, ab150157; Abcam, Cambridge, UK) was performed 
as previously described [117]. All images were acquired using a BZ-X710 microscope (Keyence, 
Osaka, Japan) and data were analysed using a BZ-H3 Analyzer (Keyence, Osaka, Japan) and data 
were analysed using a BZ-H3 Analyzer (Keyence, Osaka, Japan).. Adipocyte cell size was 
measured using ImageJ software (National Institutes of Health, Bethesda, MD) and at least 300 
cells were counted in each sample. 
 
2.6 Western blotting 
Western blotting was performed as previously described [115]. Aliquots of whole cell lysate (30 
µg) proteins extracted from BAT or iWAT were loaded onto 10% SDS-PAGE gels and transferred 
to PDVF membranes (Millipore, Darmstadt, Germany). Membranes were probed with anti-UCP-1 
(1:1000, ab10983; Abcam, Cambridge, UK) and anti-GAPDH (1:5000, sc-32233; Santa Cruz 
Biotechnology, Dallas, Texas, USA) followed by horseradish peroxidase (HRP)-conjugated anti-
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mouse or anti-rabbit IgG (Cell Signaling Technology Japan, Tokyo, Japan). Immune complexes 
were visualized using enhanced chemiluminescence (GE Healthcare Japan, Tokyo, Japan). 
2.7 RNA extraction and quantitative real-time PCR (qRT-PCR)  
Total RNA was extracted from BAT, iWAT, eWAT and liver and used for cDNA synthesis and 
qRT-PCR as described previously [115-118]. Primer sequences for Adrb3, Aldh3a2, Cs, Elovl3, 
Fgf21 and Ffar4 are listed in Table 5. The mRNA levels of these genes were normalized relative 
to cyclophilin mRNA and expressed relative to the appropriate experimental control using the 
ΔΔCT method.  
 
2.8 Statistical analysis 
All data are expressed as the mean ± SEM. Data were compared using Student’s t-test (between 
two groups) or analysis of variance (ANOVA; more than two groups) followed with scheffe post 
hoc analysis and were considered statistically significant if p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
	 16	
Chapter 3. Results  
3.1 Octacosanol and policosanol prevent HFD-induced obesity 
To investigate the effect of octacosanol and policosanol on the development of obesity, male 
C57BL/6 mice were fed on normal chow, HFD, or HFD treated with octacosanol or policosanol 
(HFDO/P) for four weeks. The body weight (BW) of HFD-fed mice was significantly higher than 
that of chow-fed mice. Treatment with octacosanol or policosanol suppressed the HFD-induced 
BW gain (Fig. 5A, B). The fat mass gain was significantly less in mice fed on HFDO/P compared 
with HFD-fed mice (Fig. 5C). The lean body mass tended to reduce in mice fed on HFDO/P 
compared with chow- or HFD-fed mice (Fig. 5D). Total body fat percentage was also significantly 
lower in mice fed on HFDO/P (Fig. 5E). The weight of epididymal WAT (eWAT) (Fig. 5F), iWAT) 
(Fig. 5G) and BAT (Fig. 5H) was significantly reduced in HFD-fed mice supplemented with 
octacosanol and policosanol. 
 
3.2 Octacosanol or policosanol treatment reduces plasma insulin levels in HFD-fed mice 
Figure 6 compares plasma metabolic parameters in four dietary groups; Chow fed, HFD fed, HFD 
treated with octacosanol or policosanol on the 4h fasted condition. Plasma glucose levels did not 
show a significant increase in the HFD group compared with the chow group (Fig. 6A). The 
treatment of HFDO/P did not change plasma glucose levels. Plasma insulin levels were markedly 
increased in the HFD group (Fig. 6B), demonstrating that HFD causes insulin resistance. 
Conversely, insulin resistance induced by the HFD was efficiently attenuated by the HFDO/P, as 
reflected in significantly decreased plasma insulin levels than in the HFD group. Previous studies 
have shown that octacosanol supplementation alters hepatic and serum lipid concentrations in 
mice [73,90]. However, HFD-fed mice treated with octacosanol or policosanol showed no 
significant reduction in the plasma levels of TG, TC), and FFA (Fig. 6C–E). 
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3.3 Octacosanol and policosanol activate BAT in HFD-fed mice 
Previous studies have shown that orally administered octacosanol was distributed to adipose 
tissue, especially BAT, and is partly oxidised and degraded to FAs through β-oxidation [104-106]. 
Thus, we investigated the effects of octacosanol and policosanol on BAT (Fig. 7). Histological 
analysis revealed that BAT of HFD-fed mice showed markedly enlarged adipocytes compared 
with that of chow-fed mice (Fig. 7A). However, the HFDO/P prevented HFD-induced enlargement 
of adipocytes in BAT, indicating reduced lipid accumulation within the tissue probably because 
they were used more as a metabolic fuel. Western blot analysis showed that protein levels of UCP-
1 were significantly increased by the HFDO/P (Fig. 7B,C). Moreover, UCP-1 
immunohistochemistry further revealed higher levels of UCP-1 in the BAT of HFDO/P –fed mice 
compared with that of chow- or HFD fed mice (Fig. 7D). The expression of thermogenic genes, 
including UCP-1, peroxisome proliferative activated receptor, gamma, co-activator 1α (Ppargc1a), 
 β3-adrenergic receptor (Adrb3), FFA receptor 4 (Ffar4) and Elovl3 were significantly increased in 
BAT of mice fed on HFDO/P (Fig. 7E). Furthermore, mice fed on HFDO/P exhibited a higher core 
body temperature than chow- or HFD-fed mice (Fig. 7F). These results suggest that octacosanol 
and policosanol activate adaptive thermogenesis and energy expenditure through the upregulation 
of thermogenic gene expression.  
 
3.4 Octacosanol and policosanol promote beiging of iWAT in HFD-fed mice 
Beiging of iWAT has been highlighted as a new possible therapeutic target for obesity, diabetes 
and lipid metabolic disorders because browning of iWAT is known to increase energy expenditure 
and reduce adiposity. Since our results suggest that octacosanol and policosanol activate non-
shivering thermogenesis in BAT and reduce body fat, we assessed the effect of octacosanol and 
policosanol on iWAT. Histological analysis showed large adipocytes in iWAT in HFD-fed mice; 
however, mice fed on HFDO/P showed significantly smaller adipocytes in iWAT (Fig. 8A,B). Next, 
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we examined whether the diminished adipocyte size in mice fed on HFDO/P could be the result of 
increased beiging of iWAT. As expected, we found that the HFDO/P increased the expression of 
genes involved in adaptive thermogenesis, such as Ppargc1a, PR domain containing 16 (Prdm16), 
Ppara, cell death-inducing DNA fragmentation factor, alpha subunit-like effector A (Cidea) and 
Ffar4, as well as citrate synthase (Cs), a crucial component of the tricarboxylic (TCA) cycle of 
mitochondria (Fig. 8C). However, we unexpectedly found that the mRNA levels of UCP-1 and its 
transcriptional regulator PPAR gamma (Pparg) and the protein levels of UCP-1 was not increased 
in the iWAT of HFDO/P –fed mice (Fig. 8C-E). These data suggest that octacosanol and policosanol 
activate energy combustion but do not fully promote the iWAT beiging in HFD-fed mice. 
 
3.5 Octacosanol and policosanol reduce adipocyte size and lower inflammation in epididymal 
WAT (eWAT) in HFD-fed mice 
We also examined the effect of octacosanol and policosanol on eWAT. Histological analysis 
showed reduced adipocyte size in eWAT of mice fed on HFD treated with octacosanol or 
policosanol (Fig. 9A, B). Since octacosanol possesses anti-inflammatory activity [77-79], we 
examined the effects of octacosanol and policosanol on HFD-induced adipose tissue 
inflammation. Immunohistochemical staining of eWAT sections for CD68, a marker of infiltrated 
macrophage revealed that crown-like structures in mice fed on HFDO/P were markedly reduced 
relative to mice fed on HFD (Fig. 9C). Moreover, the expression of genes associated with 
inflammation including F4/80, CD68, tumor necrosis factor α (Tnfa) and interleukin 1 β  (Il1b) 
was markedly upregulated in the eWAT of mice fed on HFD (Fig. 9D). The induction of these 
genes was suppressed in mice fed on HFDO/P. These results suggest that, besides preventing fat 
accumulation in WAT, octacosanol and policosanol also prevent HFD-induced adipose tissue 
inflammation. 
 
	 19	
 
3.6 Octacosanol and policosanol attenuate fatty liver in HFD-fed mice 
Liver regulates energy metabolism in the body through the dynamic control of glucose and lipid 
metabolism. Therefore, we investigated the effect of octacosanol and policosanol on the liver. The 
weight of liver in HFD-fed mice was lower than in chow-fed mice (Fig. 10A); however, HFD 
markedly increased hepatic levels of TG and TC (Fig. 10B, C). While the liver weights were 
similar between HFD-fed mice and HFDO/P –fed mice (Fig. 10A) hepatic levels of TG and TC 
were significantly lower in HFDO/P  group compared with the HFD group (Fig. 10B, C). These 
results suggest that octacosanol or policosanol supplementation attenuates the increase in hepatic 
TG and TC levels caused by HFD. The expression of genes involved in lipogenesis and β-
oxidation was analysed by quantitative PCR (qPCR) (Fig. 10D). Expression levels of sterol 
regulatory element-binding protein-1c (Srebf1c) and its downstream genes involved in lipogenesis 
such as FA synthase (Fasn), Elovl6, stearoyl-CoA desaturase-1 (Scd1) and glycerol-3-phosphate 
acyltransferase, mitochondrial (Gpam) were significantly increased in the HFD-fed mice 
compared with the chow-fed mice. Expression levels of Elovl6 and Gpam in mice fed on HFDO/P, 
and of Srebf1c and Fasn in mice fed on HFD treated with policosanol were significantly lower 
than in HFD-fed mice. Expression levels of peroxisome proliferator activated receptor alpha 
(Pparα) and its target genes involved in β-oxidation, including carnitine palmitoyltransferase 1a 
(Cpt1a) and acyl-Coenzyme A dehydrogenase, medium chain (Acadm), were significantly 
increased in the HFD-fed mice compared with the chow-fed mice. HFDO/P significantly reduced 
Pparα expression; it also reduced the expression levels of Cpt1a and Acadm, although the 
reduction was non-significant. We also examined the expression levels of genes involved in 
cholesterol biosynthesis and uptake. Results showed that the treatment of octacosanol or 
policosanol significantly suppressed HFD-induced increase in the expression of low-density 
lipoprotein receptor (Ldlr) (Fig. 10E). Moreover, the treatment of HFDO/P tended to reduce the 
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expression levels of Srebf2, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (Hmgcs1) and 
octacosanol treatment significantly reduced 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
(Hmgcr) expression. The expression levels of lipoprotein lipase (Lpl), the rate-limiting enzyme to 
catalyse the hydrolysis of TG in circulation, are similar in all groups. Collectively, these results 
suggest that octacosanol and policosanol ameliorate the development of HFD-induced fatty liver 
by suppressing the biosynthesis of FAs and TGs and uptake of cholesterol by the liver. 
 
3.7 Octacosanol activates BAT and promotes beiging in normal chow-fed mice 
To examine whether the higher BAT and iWAT function in HFD-fed mice treated with 
octacosanol is not solely due to HFD feeding, we investigated the effect of octacosanol on 
standard chow-fed mice. Mice fed on standard chow supplemented with octacosanol for six days 
showed significantly higher mRNA levels of genes involved in BAT function, including Ucp-1, 
Ppargc1a, Adrb3, Ffar4 and fibroblast growth factor 21 (Fgf21) (Fig. 11A). Similarly, higher 
mRNA levels of Ucp-1 and other beiging marker genes were observed in the iWAT of mice fed on 
standard chow treated with octacosanol (Fig. 11B). Moreover, expression levels of Elovl6 and 
Elovl3, genes encoding FA elongases involved in the biosynthesis of long chain and very long 
chain saturated FAs, were significantly increased in BAT and tended to increase in iWAT, 
respectively, following octacosanol treatment. These data suggest that octacosanol activates BAT 
and iWAT not only in mice fed on HFD but also in mice fed on chow. 
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Table 1. List of selective β3AR agonist drugs 
 
Drug Status 
BRL37344 Improves glucose utilization. 
No human studies 
CL316,243 Animal studies are still continued.  
Human studies are discontinued. 
Rafabegron Treatment of overactive bladder 
Mirabegron Treatment of overactive bladder. 
BAT activated in rats and humans. 
Solabegron Treatment of overactive bladder 
Amibegron Discontinued 
ICID7114 No effect on humans 
ZD7114 No effect on BAT 
Talibegron 
(ZD2079) 
Increase in energy expenditure is very minimal 
L-796568 Minimal effect on energy expenditure 
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Table 2. Norepinephrine elevators 
 
Drug Name Specific target(s) Current status 
Norepinephrine (NE)  
éNE 
Used in the treatment of critically  
low blood pressure. 
BAT activation in mice 
Ephedrine éNE-like activity BAT activated in humans and  
mice 
Atomoxetine éNE levels BAT activation in mice 
Nisoxetine éNE levels BAT activated in mice. 
No human studies 
Sibutramine Serotonin-norepinephrine  
uptake inhibitor 
Reduces appetite and promote  
Weight loss.  
Serious cardiovascular side-effect 
Milnacipram Serotonin-norepinephrine  
uptake inhibitor 
Control weight gain in 
 fibromyalgia patients 
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Table 3. List of glitazones 
 
Drugs Status 
Rosiglitazone éBAT lipogenesis. 
Serious side effects 
Ciglitazone êblood glucose, triglycerides, and 
food intake. Not in use 
Troglitazone Used as an anti-diabetic drug. 
Severe liver damage, discontinued 
Pioglitazone Treatment of T2D 
Severe bladder damage in some cases 
Balaglitazone ê glucose levels. 
Rivoglitazone êglucose levels by improving 
insulin resistance Under trial 
Darglitazone BAT size increased in rats. 
Serious side-effects 
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Table 4. Category 4 drugs: natural and other products 
 
Drug Name Specific target(s) Current status 
Nicotine Nicotine receptor agonist BAT activated in rats 
Forskolin Adenylate cyclase activator  
to produce cAMP 
BAT activated in mice 
Caffeine Potential mechanism via  
adenosine receptors 
Activates BAT  
thermogenesis 
Capsacin Increases UCP1 expression Increases energy  
expenditure by activation 
 of BAT 
Curcumin Various mechanism 
 including PPAR-y 
Stimulates human  
adipocyte differentiation 
Rimonabant Cannabinoid CB-1  
receptor inverse agonist 
CNS side effects.  
Drug discontinued 
SHK186 Potassium ion channel  
blocker 
BAT activation in mice 
Fibroblast growth factor 21 (FGF21) Endocrine factor present 
 in liver, pancreas and  
adipose tissue 
Energy expenditure  
may be associated with BAT 
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Table 5. Primer Sequence information for the quantitative real-time PCR analysis 
Gene Forward primer Reverse primer 
Adrb3 CCTTGGGCGAAACTGGTG GTTGGTGACAGCTAGGTAGCG 
 
Aldh3a2 TTCTCGTAACAATAAGCTCATCAAACG 
 
CAGCATCCCCAGCCTTCCTTTGTTG 
 
Cs GGACAATTTTCCAACCAATCTGC 
 
TCGGTTCATTCCCTCTGCATA 
 
Elovl3 TTCTCACGCGGGTTAAAAATGG 
 
GAGCAACAGATAGACGACCAC 
 
Ffar4 ACCAAGTCAATCGCACCCAC 
 
GTGAGACGACAAAGATGAGCC 
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Figure 1. Obesity : a imbalance between energy intake and energy expenditure 
Obesity is the consequence of imbalance in energy intake and energy expenditure. Energy 
intake comesfrom food consumption, whereas the vital givers to expenditure are exercise 
and basic metabolic processes. Energy is stored in the form of TGs in the WAT while the 
stored energy is utilised by brown adipose tissue to generate heat. 																		
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Figure 2. The three distinct fat cells. 
Brown fat cell  fat: converts chemical energy to heat and burns fat, brite fat cells: White fat 
cells that can act like brown fat cell and burns fat to dissipate energy as heat, white fat 
cells: most common fat cell, used to store fat. 																							
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Figure 3. Possible drug sites on BAT for its activation 
First category of drugs act on the cell membrane bound β3AR, which triggers the cascade 
of events via cAMP. Category 2 drugs acts on the norepinephrine transporter (NET) and 
increases norepinephrine (NE) content, which stimulates β3AR. Category 3 drugs activate 
PPAR- γ and category 4 drugs acts on various other pathways within BAT. 																
	 29	
						
		
 
 
Figure 4. Conversion of fatty alcohol into fatty acids. 
Fatty alcohol dehydrogenase (FADH) and fatty aldehyde dehydrogenase (FALDH) catalyse 
the conversion of fatty alcohol into fatty acid. 	
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Figure 5. Effect of octacosanol and policosanol on body weight, body composition and fat 
accumulation in mice fed on chow, high fat diet (HFD) and HFD treated with octacosanol or 
policosanol. (A, B) Body weight (A) and body weight gain (B) of mice fed on chow, HFD and HFD 
treated with octacosanol or policosanol (60 mg/kg/day) for four weeks (n = 7–8). (C–E) Changes in fat 
mass (C), lean mass (D) and percent fat (E) measured by dual-energy X-ray absorptiometry (DEXA) 
analysis (n = 5). (F–H) Weight of epididymal white adipose tissue (eWAT) (F), inguinal WAT (iWAT) (G), 
brown adipose tissue (BAT) (H) of mice fed on chow, HFD and HFD treated with octacosanol or 
policosanol for four weeks (n = 7–8). Values represent mean ± standard error of mean (SEM). *P < 0.05, 
**P < 0.01, ***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test. 
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Figure 6. Effect of octacosanol and policosanol on plasma metabolic parameters of mice fed 
on chow, HFD and HFD treated with octacosanol or policosanol. (A–E) Concentrations of 
blood glucose (A), plasma insulin (B), plasma triglycerides (TGs) (C), plasma total cholesterol 
(TC) (D) and plasma free fatty acids (FFA) (E) of mice fed on chow, HFD and HFD treated with 
octacosanol or policosanol for four weeks (n = 5). Values represent mean ± SEM. *P < 0.05, **P 
< 0.01, ***P < 0.001 by using one-way ANOVA followed by scheffe post hoc test.  
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Figure 7. Effect of octacosanol and policosanol on brown adipose tissue (BAT) of mice fed on 
chow, HFD and HFD treated with octacosanol or policosanol. (A) Representative hematoxylin and 
eosin (H&E)-stained sections of BAT harvested from mice fed on chow, HFD and HFD treated with 
octacosanol or policosanol for four weeks. (B) Western blotting of UCP-1 and GAPDH in BAT (n = 5). 
GAPDH was used as a loading control. (C) Protein expression of UCP-1 determined by densitometry 
analysis (n = 5). (D) Representative immunohistochemical staining for UCP-1 in BAT sections of mice 
fed	on	chow,	HFD	and	HFD	treated	with	octacosanol	or	policosanol	for	four	weeks	, scale bar 30um. 
(E) Quantitative real-time PCR (qRT-PCR) analysis of genes involved in thermogenesis of BAT in mice 
fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks (n = 5–8). (F) Rectal 
temperature of mice fed on chow, HFD and HFD treated with octacosanol or policosanol for four weeks 
(n = 5). Values represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by using one-way ANOVA 
followed by scheffe post hoc test. 
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Figure 8. Effect of octacosanol and policosanol on inguinal white adipose tissue (iWAT) of mice fed 
on chow, HFD and HFD treated with octacosanol or policosanol. (A) Representative H&E-stained 
sections of iWAT harvested from mice fed on chow, HFD and HFD treated with octacosanol or 
policosanol for four weeks. Scale bar = 30 µm. (B) Average adipocyte size in iWAT of mice fed on chow, 
HFD and HFD treated with octacosanol or policosanol for four weeks (n = 5). (C) qRT-PCR analysis of 
beige fat markers in iWAT harvested from mice fed on chow, HFD and HFD treated with octacosanol or 
policosanol for four weeks (n = 5–8). (D) Western blotting of UCP-1 and GAPDH in iWAT (n = 4–5). 
GAPDH was used as a loading control. (E) Protein expression of UCP-1 determined by densitometry 
analysis (n = 4–5). Values represent mean ± SEM *P < 0.05, **P < 0.01, ***P < 0.001 by using one-
way ANOVA followed by scheffe post hoc test. 
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Figure 9. Effect of octacosanol and policosanol on epididymal WAT (eWAT) of 
mice fed on chow, HFD and HFD treated with octacosanol or policosanol. (A) 
Representative H&E-stained sections of eWAT harvested from mice fed on chow, 
HFD and HFD treated with octacosanol or policosanol for four weeks. Scale bar = 30 
µm. (B) Average adipocyte size in eWAT of mice fed on chow, HFD and HFD treated 
with octacosanol or policosanol for four weeks (n = 5). (C) Representative 
immunohistochemical staining for CD68 in eWAT sections of mice fed on chow, HFD 
and HFD treated with octacosanol or policosanol for four weeks, scale bar 20um. (D) 
qRT-PCR analysis of genes involved in the inflammation of iWAT harvested from 
mice fed on chow, HFD and HFD treated with octacosanol or policosanol for four 
weeks (n = 5). Values represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 
by using one-way ANOVA followed by scheffe post hoc test. 
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Figure 10. Effect of octacosanol and policosanol on the liver of mice fed on chow, HFD 
and HFD treated with octacosanol or policosanol. (A–C) Liver weight (A) and hepatic 
levels of TGs (B) and TC (C) in mice fed on chow, HFD and HFD treated with octacosanol or 
policosanol for four weeks (n = 5–8). (D, E) qRT-PCR analysis of genes involved in fatty acid 
(FA) metabolism (D) and cholesterol biosynthesis (E) in livers harvested from mice fed on 
chow, HFD and HFD treated with octacosanol or policosanol for four weeks (n = 5). Values 
represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by using one-way ANOVA 
followed by scheffe post hoc test.  
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Figure 11. Effect of octacosanol on gene expression in BAT and iWAT harvested from 
mice fed a chow diet. (A, B) qRT-PCR analysis of genes involved in thermogenesis and 
energy expenditure of BAT (A) and iWAT (B) in mice fed on chow, with or without 
octacosanol treatment, for seven days (n = 5). Values represent mean ± SEM. *P < 0.05, **P < 
0.01, ***P < 0.001 vs. control (vehicle-treated) mice by using student-t-test.  
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Figure 12. 
Effect of octacosanol and policosanol on the expression of Aldh3a2 in BAT and iWAT 
from mice fed a normal chow or HFD. 
(A) Quantitative real-time PCR analysis of Aldh3a2 in BAT and iWAT from chow-fed mice 
treated with or without octacosanol or policosanol for 4 weeks. Values represent means ± 
SEM (n=5). * P < 0.05, **P < 0.01, ***P < 0.001. (B) Quantitative real-time PCR analysis 
of Aldh3a2 in BAT and iWAT from chow-fed mice treated with or without octacosanol for 7 
days. Values represents means ± SEM (n=5). *P < 0.05, **P < 0.01, ***P < 0.001 vs 
vehicle-treated control 
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Chapter 4. Discussion  
 
This study aimed to determine whether purified octacosanol and policosanol have beneficial 
effects on HFD-induced obesity in mice. We showed that both octacosanol and policosanol 
significantly ameliorated HFD-induced fat gain and fatty liver. Furthermore, octacosanol and 
policosanol activated signalling pathways that regulate thermogenesis and enhance energy 
expenditure in BAT and iWAT. 
Several factors are involved in energy expenditure and thermogenesis in BAT and beige fat 
[11,12]. Policosanol is a fatty alcohol, which is converted to saturated and monounsaturated FAs 
by fatty aldehyde dehydrogenase (FALDH, alternatively known as Aldh3a2) [108,109]. Fatty 
aldehydes are also implicated in thyroid function [119], cell proliferation [120], adipogenesis and 
signalling pathways involving PPARγ [121]. In this study, we also observed higher expression of 
Aldh3a2 in BAT and iWAT of chow- or HFD-fed mice treated with octacosanol or policosanol 
(Fig. 12), suggesting the conversion of octacosanol and policosanol into FAs. Previous studies 
have suggested that orally administrated octacosanol and policosanol may be oxidised and 
degraded into shortened saturated and monounsaturated FAs via β-oxidation in vivo [104-106]. 
Additionally, long chain and very long chain saturated and monounsaturated FAs synthesized via 
Elovl6 and Elovl3 regulate mitochondrial function and thermogenic capacity in BAT and iWAT 
[112-114] [122,123]. Our findings suggest that shortened saturated and unsaturated FAs 
metabolized from octacosanol and policosanol perform cellular functions important for 
thermogenesis and energy expenditure in BAT and WAT. Further studies are needed to confirm 
this possibility. 
Recent studies have shown that FFAR4 (GPR120), a receptor for polyunsaturated FAs (PUFAs), 
plays a pivotal role in the thermogenic activity of BAT and browning of WAT [124-126]. 
Activation of FFAR4 by n-3 PUFA or a selective agonist increases β-oxidation and reduces body 
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weight and fat mass by inducing BAT activity and promoting the browning of WAT. In this study, 
we showed that the treatment of HFD with octacosanol or policosanol induced Ffar4 expression in 
BAT and iWAT of mice and decreased lipid content in BAT and WAT. This suggests that the 
treatment of HFD with octacosanol or policosanol triggers brown/beige fat activation by 
upregulating Ffar4 expression in BAT and WAT of HFD-induced mice. 
Besides improving metabolism, octacosanol also possesses anti-inflammatory properties [77-79]. 
In obesity, a paracrine loop between adipocytes and macrophages augments chronic inflammation 
of adipose tissue, thereby inducing systemic insulin resistance and ectopic lipid accumulation 
[127]. Since adipose tissue in obese individuals is characterized by adipocyte hypertrophy and 
chronic inflammation, we also investigated the effects of octacosanol and policosanol on the 
inflammatory state of WAT. Treatment of HFD with octacosanol or policosanol lowered the 
expression levels of pro-inflammatory genes including F4/80, CD68, Tnfα and Il1b in eWAT. 
Previously, a high concentration of octacosanol has been shown to inhibit the mitogen-activated 
protein kinase/nuclear factor-kappa B/ activator protein-1 signalling pathway involved in the 
regulation of inflammation in macrophages [79]. This anti-inflammatory effect of octacosanol and 
policosanol might contribute to the improvement of systemic insulin resistance induced by HFD. 
Moreover, octacosanol and policosanol-induced FFAR4 expression might contribute toward the 
anti-inflammatory effect of octacosanol and policosanol because FFAR4 activation by n-3 PUFA 
triggers a broad spectrum of anti-inflammatory effects in macrophages [128,129]. 
Apart from the main component octacosanol (C28) (60-70%), policosanol also contains other fatty 
alcohols such as Hexacosanol (C26) (3-10%), triacontanol (C30) (10-15%) and dotricontanol 
(C32) (5-10%) [68]. However, most pharmacological effects of policosanol, including cholesterol 
reduction, have been proven for octacosanol, not for other constituent [130]. Previous studies 
investigating octacosanol biodistribution using radiolabelled octacosanol have reported that the 
highest amount of radioactivity from octacosanol was in adipose tissue, especially BAT followed 
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with perirenal adipose tissue, eWAT and liver [104]. In the liver, octacosanol may be degraded to 
FAs, which then incorporated into TGs, sterols and phospholipids. However, the presence of 
radioactivity in adipose tissue suggests that either octacosanol itself or its metabolites (FAs) were 
transported to be utilized for thermogenesis via β-oxidation. 
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Chapter 5. Conclusion 
In conclusion, we show that octacosanol and policosanol exert beneficial metabolic effects by 
activating thermogenic changes in HFD-induced obesity in mice. Although precise molecular 
mechanisms underlying the involvement of octacosanol and policosanol in the thermogenic 
activity of BAT and browning of WAT are unknown, our data shown that octacosanol is a potent 
dietary anti-obesity molecule, which increases the thermogenic activity of BAT and iWAT, thereby 
increasing energy expenditure and reducing fat mass.  	
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